

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

1617
PATENT
Attorney Docket No.: 014058-013300U

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On July 15, 2003



TOWNSEND and TOWNSEND and CREW LLP

By: Mark T. Davis

RECEIVED
JUL 21 2003
TECH CENTER 16012500
10/10

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Sally Mossman et al.

Application No.: 10/068,171

Filed: February 4, 2002

For: IMMUNOSTIMULANT
COMPOSITIONS COMPRISING
AMINOALKYL GLUCOSAMINIDE
PHOSPHATES AND SAPONINS

Examiner: Unknown

Art Unit: Unknown

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Also enclosed is a copy of the Search/Examination report corresponding to the PCT application.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Joel G. Ackerman
Reg. No. 24,307

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
JA:ja
SF 1474582 v1



PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page 1 of

Complete if Known

Application Number	10/068,171
Filing Date	February 4, 2002
First Named Inventor	Mossman, Sally, et. al.
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	014058-013300US

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	AA	US-5,977,081	11-02-1999	Marciani	
	AB	US-6,080,725	06-27-2000	Marciani	
	AC	US-6,113,918	09-05-2000	Johnson et al.	
	AD	US-6,262,029	07-17-2001	Press et al.	
	AE	US-6,303,347	10-16-2001	Johnson et al.	
	AF	US-6,355,257	03-12-2002	Johnson et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴ Kind Code ⁵ (if known)				
	AG	WO	98/57659	12-23-1998	Smithkline Beecham Biologicals		<input type="checkbox"/>
	AH	WO	99/62647	10-21-1999	Brigham Women's Hospital		<input type="checkbox"/>
	AI	WO	01/78777	10-25-2001	Corixa Corporation		<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AJ	U.S. patent application 10/068,475 filed February 4, 2002: Mossman et al., "Immunostimulant Compositions Comprising Aminoalkyl Glucosaminide Phosphates and Saponins (copending application; not yet published)	
	AK	U.S. patent application 10/177,115 filed June 21, 2002: Mossman et al., "Immunostimulant Compositions Comprising Aminoalkyl Glucosaminide Phosphate and QS-21 (copending application; not yet published)	
	AL	Wijburg et al., The Role of Macrophages in the Induction and Regulation of Immunity Elicited by Exogenous Antigens; Eur. J. Immunol. 28: 479 (1998)	
	AM	Jones et al., Immunization with Human Immunodeficiency Virus Type I rgp120 _{W81D} in QS21/MPL Adjuvant ...; J. Infect. Diseases 179: 558 (1999)	
	AN	Mioore et al., The Adjuvant Combnation Monophosphoryl Lipid A and QS21 switches T cell responses...; Vaccine 17: 2517 (1999)	


Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page

2

of

Complete if Known

Application Number	10/068,171
Filing Date	February 4, 2002
First Named Inventor	Mossman, Sally, et. al.
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	014058-013300US

RECEIVED
JUL 21 2003
TECH CENTER 1600/2900**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴ Kind Code ⁵ (If known)				
	AO	McCormack et al., A Phase I Trial in Negative Healthy Volunteers...; Vaccine 18: 1166 (2000)					
	AP	Gerard et al., Therapeutic Potential of OProtein and Adjuvant Vaccinations on Tumor Growth; Vaccine 19: 2583 (2001)					
	AQ	Johnson et al., Synthesis and Biological Evaluation of a New Class of Vaccine Adjuvants: Aminoalkyl Glucosaminide 4-Phosphates (AGPs): Bioorganic & Medicinal Chemistry Letters 9: 2273 (1999)					

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.